10 Things You Didn’t Know About Decentralized Clinical Trials

In this informative webinar, discover the future of clinical trials with decentralized clinical trials (DCT), exploring virtual operations and patient-friendly approaches. The adoption of DCT has increased exponentially in recent years. As adoption accelerates, so do the possibilities that virtual conduct enables. While DCT may seem relatively new to many, there are companies and investigators that have been delivering remote trial conduct for more than a decade.

In this webinar, attendees will discover:

• How recruitment works in a decentralized trial
• How physical exams and adverse events (AE) are managed
• How oversight is handled in a virtual site
• What procedures can be performed at home
• How to ensure proper regulatory supervision
• How the drug is shipped to the patient directly, without a physical site
• How to implement this patient-friendly approach to clinical research with insights from the industry’s top DCT investigators

Join this webinar, where the featured speakers will delve into key questions that are often asked about virtual trials and remote study conduct.

Speakers

Jonathan Cotliar, MD, Chief Medical Officer, Science 37

Dr. Jonathan Cotliar, has been the Chief Medical Officer of Science 37 since November 2016. Prior to assuming this role (from November 2016 to May 2019), Dr. Cotliar served as Vice President of Medical Affairs for Science 37, where he contributed as an Investigator on several virtual clinical trials in addition to his work in support of business development and regulatory strategy. Dr. Cotliar currently serves as Director of Inpatient Dermatology at Harbor-UCLA Medical Center, with previous full-time faculty appointments at the David Geffen School of Medicine at UCLA, Northwestern University Feinberg School of Medicine and City of Hope National Medical Center. He was Chief of the Division of Dermatology at City of Hope, previously.

Dr. Cotliar earned his BA from Trinity College, MD from the University of Kentucky College of Medicine and completed his training in dermatology and internal medicine at the David Geffen School of Medicine at UCLA. While at UCLA, he completed a NIH-sponsored K30 Fellowship in translational investigation. Dr. Cotliar is also board-certified in both internal medicine and dermatology.

Message Presenter

Debra Weinstein, MD, Vice President — Internal Medicine, Science 37

Dr. Debra Weinstein’s involvement in clinical research began in 2002 when she became involved as both a Sub-Investigator and Principal Investigator with Visions Clinical Research. In 2007, she founded her own clinical research company, ZASA Clinical Research, which has had great success in all aspects of internal medicine research. In 2009, Dr. Weinstein co-founded and became the managing member of Orthopedic Research Institute, a company specializing in rheumatologic, orthopedic, podiatric and pain management studies.

In 2011, she became one of the founding members of the Atlantic Clinical Research Collaborative (ACRC). ACRC operated as a multi-disciplinary research company with broad capabilities. Dr. Weinstein currently devotes all of her time to clinical research. Over the last 21 years, Dr. Weinstein has served as an Investigator on over 260 clinical studies. Dr Weinstein joined the team at Science 37 in October of 2017. She is currently serving as Vice President of Internal Medicine at Science 37.

Message Presenter